NEW YORK, June 1, 2012 /PRNewswire/ -- WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, announced today that Cavan M. Redmond has been appointed as its new Chief Executive Officer and as a member of its Board of Directors, effective May 31, 2012. Mr. Redmond, 51, joins WebMD from Pfizer Inc., the world's largest research-based pharmaceutical company, where he most recently served as Group President, Animal Health, Consumer Healthcare and Corporate Strategy and as a member of Pfizer's Executive Leadership Team. He was responsible for two diverse businesses while leading Pfizer's enterprise-wide Strategy, R&D Portfolio Management and Analysis, Global Commercial Operations and Continuous Improvement.
"Cavan brings unparalleled expertise and leadership in both biopharmaceutical and consumer healthcare to WebMD, and we are excited to welcome him to the WebMD team," said Martin J. Wygod, Chairman, WebMD. "He has a successful track record in identifying and leveraging new revenue opportunities, driving efficiency and establishing sustainable growth platforms. Along with our experienced management team, I have great confidence that Cavan will take WebMD to the next level. Cavan's proven ability to drive strategy and leverage the value of brands will be invaluable as WebMD continues to define and lead the market for digital health information."
Mr. Redmond has more than 20 years of healthcare experience encompassing a broad range of global healthcare businesses including biotechnology, pharmaceuticals, consumer healthcare and infant nutritionals. Mr. Redmond is a global healthcare strategist with a demonstrated ability to implement complex strategies in highly competitive and regulated markets. His strength in new product development, marketing, strategy and technology has resulted in a proven track record of building global brands, starting new businesses and reenergizing existing businesses. His biopharmaceutical experience also includes leading global strategic marketing, marketing research and analytics, new product marketing and multi-channel marketing programs. Prior to Pfizer's acquisition of Wyeth, Mr. Redmond served as the first Executive Vice President and General Manager of Wyeth's high-growth BioPharma Business Unit where he was responsible for the creation of the global biopharma business and grew the business significantly.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts